Combination Therapy, Targeted Therapy
Approved for: NSCLC
Biomarker: BRAF
Dabrafenib (Tafinlar) is a FDA-approved Targeted Therapy/Combination Therapy for non-small cell lung cancer that has metastasized (NSCLC) with the biomarker BRAF. It is used with trametinib. Dabrafenib is used only in patients whose cancer has a certain mutation in the BRAF gene.
